Hofseth Biocare ASA: HBC HIRES EX DKSH SENIOR EXECUTIVE DR TANJA SCHAFFER, TO HEAD UP ITS GLOBAL INGREDIENTS BUSINESS AND AS CEO OF HBC SWITZERLAND GMBH
September 17 2021 - 2:02AM
Hofseth Biocare ASA: HBC HIRES EX DKSH SENIOR EXECUTIVE DR TANJA
SCHAFFER, TO HEAD UP ITS GLOBAL INGREDIENTS BUSINESS AND AS CEO OF
HBC SWITZERLAND GMBH
HBC is delighted to announce the hiring of Dr Tanja Schaffer as
Executive Vice President for HBC’s Global Ingredients division and
as CEO of HBC's new Swiss subsidiary HBC Switzerland GmbH.
The setup in Switzerland is in line with HBC's international
strategy, with Switzerland being widely recognized as a major
biotech and life science hub. A presence in Switzerland will
benefit HBC's partnerships with leading global players based in the
country as well as enable HBC to offer talents and experienced
professionals’ opportunities to engage with HBC outside of
Norway.
The operations of HBC Switzerland GmbH will initially deliver
services to HBC related to marketing, sales and organization
development, and HBC is delighted that Dr. Schaffer will assume the
position of CEO and lead the build-up of the operations in HBC
Switzerland next to the development of the global ingredients
business.
Dr Schaffer is a highly accomplished commercial leader with over
15 years’ experience at taking scientific ingredients to market.
She began her career as Head of the Scientific Department of Lipoid
GmbH after attaining her PhD in Physical Chemistry at the
University of Regensburg in Germany. Following this, she joined
AllessaChemie as a business development manager and then was
swiftly promoted to Director of Marketing and Business Development
before joining DKSH in 2011. For the last seven years she has held
the position of VP of Global Pharmaceuticals Industry within DKSH,
where she was responsible for 26 sales teams globally, four
sourcing teams and several applications laboratories. Of note she
was also responsible for the Animal nutrition line with the
Performance materials division of DKSH as well as nutraceuticals in
various Asian markets. As such, she brings a wealth of both
technical know-how and commercial knowledge and relationships to
help grow HBC’s business.
Dr Tanja Schaffer says: “I am very happy to join the great team
of Hofseth Biocare and getting the opportunity to further develop
the market for HBC’s innovative, sustainable and science-based
products. I am looking very much forward to being part of the
dynamic team and to bring HBC´s science to market. I believe the
product have enormous market potential to be sold globally across
multiple channels in both food applications and medical
nutrition.“
Dr Schaffer’s leadership is now part of a wider strategy to
commercialise and grow the branded ingredients business,
strategically located in Switzerland, geographically located in the
centre of Europe and a global capital for life-sciences, food, and
ingredients. The there is a huge potential to develop the sales of
sustainable human grade ingredients in multiple categories
including clinical nutrition, women’s health and fertility, GI
health and sports nutrition. Unique and natural anti-inflammatory
and antioxidant effect are now all the more desirable after the
Covid-19 pandemic and future work will continue to show the product
differentiation HBC processes. Shifting sales from the commoditised
animal feed markets towards the much higher value human and pet
supplement market will gather apace in 2022.
HBC has been targeted in its recruitment for best-in-class human
talent from global leading companies in pharma and nutraceutical
businesses to support its strategy. DKSH itself is a major part of
a specialised distributor B2B strategy with HBC to help give it
global reach to brands it would not otherwise touch. Dr Schaffer’s
addition will also help catalyse this existing relationship even
more.
Roger Hofseth says: “Hiring Tanja Schaffer is an extraordinary
opportunity for HBC, and we are delighted to have her onboard.
Hiring a senior leader directly from one of the world’s leading
global ingredients market expansion teams, with such specialised
product knowledge and sales experience is testament to the
opportunity that HBC offers its customers. She will not only help
develop our own brand formulations and provide deeper technical
expertise but also focused on selling unique health claims with a
second to none sustainability profile. Her deep understanding of
what Ingredient customers are looking for will help grow our sales
and further strength a close relationship with DKSH itself, which
is itself purely focused on opening markets in Asia for us. Her
position will also help catalyse the excellent partnership with
IMCD in Europe and the Americas to expand our reach globally.”
For further information, please contact:James Berger CCO at
Hofseth BioCare ASAPhone: +41 79 950 1034E-mail:
jb@hofsethbiocare.no
About Hofseth BioCare ASA:HBC is a Norwegian biotech company
that develops high-value ingredients and finished products
currently targeting the consumer health market. Research is ongoing
to identify the individual elements within the products that
modulate inflammation and the immune response with pre-clinical
studies in multiple clinics and university research labs in several
countries. Lead clinical and pre-clinical candidates are in
development for the protection of the Gastro-Intestinal (GI) system
against inflammation, including ulcerative colitis and the orphan
condition necrotising enterocolitis, as a Medical Food to help
treat age-related Sarcopenia, and as a treatment for Iron
Deficiency Anemia, all using peptide fractions of Salmon Protein
Hydrolysate. Preclinical trial work with the oil is ongoing to
ameliorate lung inflammation in eosinophilic asthma and COPD
("smoker's lung") as well as clinical work in COVID.
The company is founded on the core values of sustainability and
optimal utilization of natural resources. Through an innovative
hydrolysis technology, HBC can preserve the quality of lipids,
proteins and calcium from fresh salmon off-cuts.
Hofseth BioCare's headquarters are in Ålesund, Norway with
branches in Oslo, London, Zürich, Chicago, Mumbai, Palo Alto and
Tokyo. HBC is listed on Oslo Stock Exchange with ticker "HBC". More
information about Hofseth BioCare at www.hofsethbiocare.com
This information is subject to the disclosure requirements
pursuant to Section 5-12 of the Norwegian Securities Trading
Act
Hofseth Biocare Asa (LSE:0Q6H)
Historical Stock Chart
From Aug 2024 to Sep 2024
Hofseth Biocare Asa (LSE:0Q6H)
Historical Stock Chart
From Sep 2023 to Sep 2024